Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
767.50-
QQQ
715.130.18%
BTC/USD
78283.250.7661%
DIA
533.960.21%
GLD
408.560.08%
TLT
82.780.12%

Can Fite Biopharma Ltd

CANFAMEX
Trade with Public
Trade with Public
$3.40
0.030.89%
At close: Aug 27, 5:00 PM EST
$3.40
0.030.89%
Pre-Market: 7:02 AM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentCompareStock Report

Can Fite Biopharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Can Fite Biopharma (CANF).

Price Target Range — 10 Quarters

Analyst Consensus — 3 Analysts

3Buy
Consensus RatingBuy# Analysts3Avg. Consensus PT$11Upside to Avg. PT+216.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jul 2, 2026HC Wainwright & Co.Swayampakula RamakanthPT RaiseBuy$5→$8
May 13, 2026D. Boral CapitalJason KolbertUpgradeHold→Buy$7
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Can Fite Biopharma, Raises Price Target to $8

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Can Fite Biopharma (AMEX:CANF) with a Buy and raises the price target from $5 to $8.
Benzinga Newsdesk

PRO
D. Boral Capital Upgrades Can Fite Biopharma to Buy, Announces $7 Price Target

D. Boral Capital analyst Jason Kolbert upgrades Can Fite Biopharma (AMEX:CANF) from Hold to Buy and announces $7 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Can Fite Biopharma, Raises Price Target to $5

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Can Fite Biopharma (AMEX:CANF) with a Buy and raises the price target from $2.5 to $5.
Benzinga Newsdesk

PRO
D. Boral Capital Maintains Buy on Can Fite Biofarma, Lowers Price Target to $4

D. Boral Capital analyst Jason Kolbert maintains Can Fite Biofarma (AMEX:CANF) with a Buy and lowers the price target from $11 to $4.
Benzinga Newsdesk

PRO
D. Boral Capital Maintains Buy on Can Fite Biofarma, Maintains $11 Price Target

D. Boral Capital analyst Jason Kolbert maintains Can Fite Biofarma (AMEX:CANF) with a Buy and maintains $11 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Assumes Can Fite Biofarma at Buy, Announces Price Target of $2.5

HC Wainwright & Co. analyst Swayampakula Ramakanth assumes Can Fite Biofarma (AMEX:CANF) with a Buy rating and announces Price Target of $2.5.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved